Activating mutations in NFE2L2 can facilitate tumour progression and protect cells from chemotherapy, and occur frequently in several cancers including squamous cell lung carcinomas (LUSC)42. This evidence concerns the gene NFE2L2 and squamous cell lung carcinoma.